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Glaucoma is a leading cause of blindness worldwide \[[@CR1]\]. It is estimated that more than 60 million people had glaucoma in 2010, 8.4 million of whom are bilaterally blind as a result of the disease.There are 79.6 million people around the world who will have glaucoma by 2020, and 74 % of them will have open-angle glaucoma (OAG) \[[@CR2]\]. Lowering the intraocular pressure (IOP) is still the goal of OAG treatment and remains the most effective way to prevent the development and progression of glaucoma. Currently, there are three methods available to achieve this goal: medication, laser treatments, and surgery \[[@CR3]\].

Medication therapy is typically the first approach for reducing IOP. Currently, many kinds of potently hypotensive topical medicines are available for controlling IOP \[[@CR4]\]. However, medications have potential disadvantages. Patients must tolerate drug side effects, repeated application of drugs and ongoing medical costs \[[@CR5]\]. The introduction of selective laser trabeculoplasty (SLT) provided a new non-invasive choice for the reduction of IOP in eyes with OAG \[[@CR6]\]. This treatment consists of the application of laser spots in the trabecular meshwork which leads to an increase in the outflow facility and, consequently, decreases IOP.

In a previous Cochrane systematic review on laser trabeculoplasty, only one study comparing SLT with medication was included, which prevented the meta-analysis at that time \[[@CR3]\]. In a recent meta-analysis comparing SLT with argon laser trabeculoplasty (ALT) in the treatment of OAG, the role of medication also was not evaluated \[[@CR7]\]. Thus,the effectiveness of SLT compared to contemporary medication requires further investigation. Recently, McAlinden et al. \[[@CR8]\] reviewed the IOP-lowering effect when comparing SLT to other glaucoma treatment options. In that article, the author only described the effects of SLT and did not perform a meta-analysis.

Currently, several published clinical trials have compared the efficacy and safety of SLT with medical therapy \[[@CR9]--[@CR13]\]. For example, Lai et al. \[[@CR13]\] reported that the IOP-lowering effect of SLT in Chinese patients is comparable with topical medications. However, these studies had modest sample sizes and conveyed inconclusive results. To date, no consensus has been reached on this topic. Previously, we conducted a meta-analysis comparing SLT with ALT; the results reveal that SLT has similar efficacy to ALT with a similar constellation of side effects \[[@CR14]\]. To our knowledge, the data comparing SLT with topical medication in the treatment of OAG has not been systematically evaluated and reported. Therefore, we conducted a systematic review and meta-analysis of all published prospective clinical trials to assess the outcomes of SLT versus medication in the treatment of OAG.

Methods {#Sec2}
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The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used as a guide to conduct the study, including the strategies for searching, analysis, the presentation of results, potential bias, interpretation, and writing (Additional file [1](#MOESM1){ref-type="media"}: Table S1) \[[@CR15]\].

Literature search and trial selection {#Sec3}
-------------------------------------

Studies were identified and retrieved through a systematic search of PubMed, Embase, the Web of Science, the Chinese Biomedicine Database, and the Cochrane Controlled Trials Register database from their inception up to March 2014. Periodical literature update was performed and the most recent literature retrieving was at June 30, 2015. However, no new original articles comparing SLT to medication was identified. Keywords used in identifying relevant researches included 'selective laser trabeculoplasty', 'Yag laser trabeculoplasty', 'selective laser trabeculectomy', 'Nd:YAG', 'SLT', 'glaucoma', and 'ocular hypertension'. Searches were performed by combining the keywords or their relevant abbreviations and truncations. No restriction was applied for language or year of publication. The websites of professional associations and Google Scholar were also searched for additional information. Moreover, a manual search was performed by checking the reference lists of all retrieved trials to identify studies not yet included in the computerized databases. Eligible studies were prospective randomized or non-randomized comparative controlled trials, which compared the use of SLT and topical anti-glaucoma medications in adult patients with any form of naïve OAG or ocular hypertension (OHT).

Data extraction and outcome measures {#Sec4}
------------------------------------

The information on author, age, sex, country, duration, sample size, type of glaucoma, study design, and other outcome data were extracted.  The incidence of transient post-laser IOP spikes, sustained IOP elevation, anterior chamber reaction, discomfort, redness, and pain were recorded. For studies with overlaps of population, the latest one were included in the final analysis. Given that the effectiveness of OAG treatment is often assessed by the intraocular pressure reduction (IOPR) and percent of intraocular pressure reduction (IOPR %), the primary efficacy outcomes were the IOPR and IOPR % from the baseline to the end of follow up. The secondary efficacy outcome was the success rate. Success was defined as IOPR ≥ 3 mm Hg and/or IOPR % ≥20 % \[[@CR7]\]. The adverse events in each intervention were also reviewed.

Assessment of methodology quality {#Sec5}
---------------------------------

The Downs and Blacks scale, which could evaluate both randomized and non-randomized studies, were used for assessment of the clinical trials \[[@CR16]\]. The system comprises 27 items distributed between five subscales regarding reporting (10 items), external validity (three items), bias (seven items), confounding (six items), and power (one item). Any discrepancy in the qualitative assessment between the two observers was discussed and a consensus was reached. The total score of each trial was expressed as a percentage of the maximum achievable score. Studies\' methodological quality was assessed as excellent, good, fair, or poor when the total score was ≥20, from 15 to 19, from 11 to 14, and ≤10, respectively \[[@CR17]\].

Statistical analysis {#Sec6}
--------------------

The intent-to-treat analyses were used in each outcome. Additionally, data was combined using an inverse variance random-effects model regardless of heterogeneity \[[@CR18]\].The weighted mean difference (WMD) was calculated for continuous outcomes while the odds ratio (OR) was estimated for dichotomous outcomes. All results were given with 95 % confidence intervals (CIs). Heterogeneity was checked using Cochran\'s Q statistic and the P-value. I^2^ metrics, which quantify heterogeneity irrespective of the number of studies, were also reported \[[@CR19]\]. Studies with an I^2^ value of greater than 50 % were considered significant heterogeneity. A P*-*value of less than 0.05 was considered statistically significant. The statistical analysis was performed using Stata SE 12.0 (Stata Corporation LP, College Station, TX, USA).

Sensitivity analysis and publication bias {#Sec7}
-----------------------------------------

We also performed subgroup analysis in terms of the medications used within the medication group. In addition, we investigated the influence of a single study on the overall pooled estimate by omitting one study in each turn. To detect publication biases, we visually examined asymmetry in funnel plots. Furthermore, the Begg's and Egger's measures were calculated.

Results {#Sec8}
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Literature search {#Sec9}
-----------------

The initial search yielded 850 relevant publications, of which 814 were excluded for being duplicates from multiple databases or for various other reasons (unrelated topic,reviews, case reports, or case series) on the basis of the titles and abstracts. The remaining 30 were retrieved for full-text review, and 25 of them were excluded because they were studies comparing SLT with other laser therapies rather than drugs (Additional file [2](#MOESM2){ref-type="media"}: Table S2). Hence, a final total of five studies published from 2004--2012 were included in this meta-analysis \[[@CR9]--[@CR13]\]. Fig. [1](#Fig1){ref-type="fig"} provides a flow diagram of the search results.Fig. 1The selection flowchart of clinical trials included in this meta-analysis

Characteristics and quality assessment of the included studies {#Sec10}
--------------------------------------------------------------

In total, there were 492 eyes from 366 patients included in this meta-analysis; 318 eyes were included in the SLT group and 174 eyes were included in the medication group. The characteristics of the included studies are summarized in Table [1](#Tab1){ref-type="table"}. The age of patients ranged from 25--82 years. One study was a prospective non-randomized comparative trial \[[@CR11]\] and four studies were randomized clinical trials (RCT) \[[@CR9], [@CR10], [@CR12], [@CR13]\]. The studies had the following geographic distribution: one in the USA, one in China, one in Canada, and two in the UK. The mean duration of follow-up ranged from 4--60 months. In the studies included in the present meta-analysis, SLT was usually performed at 360° with an average power setting between 0.2 mJ and 1.7 mJ. The mean baseline IOP ranged from 25.0 mmHg to 29.3 mmHg in SLT groups, and from 22.8 mmHg to 29.0 mmHg in medication groups. Our prespecified definition of success was target IOP, but different and heterogeneous definitions were used in studies, such as IOP \< 21 mmHg after intervention in one study \[[@CR13]\], at least a 20 % IOP reduction from baseline measurement in three studies \[[@CR10]--[@CR12]\], and meet the target IOP in one study \[[@CR9]\]. Table 2 shows the quality evaluation of each clinical trial. The Downs and Blacks score for each study exceed 16, which indicate adequate methodological quality.Table 1Characteristics of prospective comparative controlled trials comparing SLT with topical medicationAuthor(year)Design, locationNO. of eyes (SLT/med)Follow-upMean ageBaseline IOPBCVA\
C/DDiagnosisDefinition of successDegrees of SLT/\
Average energyMedicationLai(2004)SC,RCT, China29/2960 m51.926.8 ± 5.6 /26.2 ± 4.20.1-1.0/ 0.2-1.0POAG, OHTIOP ≤ 21 mmHg360Topical beta-blocker, pilocarpine, dorzolamide latanoprost as monotherapy or in combination0.4 ± 0.2/ 0.5 ± 0.21.0 ± 0.1 mJNagar(2005)MC,RCT, UK128/3912 m6329.3/29NAPOAG, OHT, PDS, PEXIOPR% ≥ 20 %360/180/90Latanoprost 0.005 %0.2-1.7 mJMcIlraith(2006)MC,Pro, Canada74/2612 m6226/24.6NAPOAG, OHT, PDS, PEXOP ≤ 22 mmHg180Latanoprost 0.005 %0.5 ± 0.2/ 0.6 ± 0.20.8 mJNagar(2009)SC,RCT, UK20/204-6 mNR26.1 ± 4.0 /22.8 ± 4.5NAPOAG, OHTIOPR% ≥ 20 %360Latanoprost 0.005 %0.2-1.4 mJKatz(2012)MC,RCT, USA67/609-12 mNR25.0 ± 2.2 /24.5 ± 2.2NAPOAG, PEX, OHTArrived target IOP360 followed by 180 0.2-1.2 mJTopical prostaglandin analog, β-blocker, brimonidine, carbonic anhydrase inhibitor, in combinationAbbreviations: SLT = selective laser trabeculoplasty; M/F = male/female; m = month; NA = not available. SC = single center, MC = multi-center, RCT = randomized controlled trial; Pro = prospective non-RCT; intervention = SLT/medication; BCVA = best corrected visual acuity; C/D = cup to disc ratio; POAG = primary open angle glaucoma; OHT = ocular hypertension; PDS = pigment dispersion syndrome; PEX = pseudoexfoliation syndromeTable 2Quality scoring components for five clinical trials included in the meta-analysisQuality score componentScoreFirst Author (year)IIIIIIIVVOver allPercentage (%)Lai(2004)1125332475.00 %Nagar(2005)1134332471.88 %McIlraith(2006)924221959.38 %Nagar(2009)1134332471.88 %Katz(2012)1134332471.88 %I = reporting; II = external validity; III = bias (seven items); IV = confounding; V = power

IOP reduction {#Sec11}
-------------

Four studies involving 325 eyes compared SLT with medication in terms of the IOPR (Fig. [2](#Fig2){ref-type="fig"}). No statistical heterogeneity was observed between studies (χ2 = 1.30, P = 0.75, I^2^ = 0.0 %). SLT was found to archive a numerically greater IOPR from baseline to end-point; however, the differences in the IOPR were not all statistically significant (WMD = 0.6, 95 % CI: −0.24, 1.43) (Table [3](#Tab3){ref-type="table"}). We divided the studies into 3 subgroups according medication, and then performed a sensitivity analysis excluding the non-randomized study.Fig. 2Comparison of intraocular pressure reduction from the baseline between SLT group and topical medication group. WMDs indicate weighted mean difference, which were computed by using a random-effects modelTable 3Subgroup analysis of IOP reduction from the baseline and success rate comparing SLT with medicationGroupNo. of studiesWMD/ORTest for HeterogeneityTest for Overall EffectEstimateLowerUpχ2I^2^PZPAll40.60−0.241.431.300.00 %0.7301.400.163Only RCT30.86−0.191.900.650.00 %0.7231.600.110Combined medication20.64−0.551.830.090.00 %0.7671.050.292Latanoprost-only20.61−0.731.941.2016.4 %0.2740.890.374**IOPR%**All4−1.90 %−5.00 %1.10 %3.7820.50 %0.2871.230.220Only RCT3−3.20 %−9.10 %2.70 %3.7747.00 %0.1521.060.290Combined medication2−0.80 %−3.20 %1.50 %0.000.00 %0.9880.670.502Latanoprost-only2−5.10 %−13.50 %3.20 %2.4559.2 %0.1171.200.230All50.840.421.685.9833.1 %0.2000.500.621Only RCT40.850.342.115.9849.8 %0.1130.350.726Combined medication21.460.613.490.230.00 %0.6290.850.396Latanoprost-only30.570.231.382.8529.9 %0.2401.260.209IOP = intraocular pressure; SLT = selective laser trabeculoplasty; IOPR = intraocular pressure reduction; IOPR %  = percent intraocular pressure reduction from baseline; Pro = prospective nonrandomized; RCT = prospective randomized controlled trial; OR = odds ratio;

All subgroups showed that SLT was similar to medication in IOPR (Table [3](#Tab3){ref-type="table"}). Four studies reported the IOPR % at follow-up endpoint (Fig. [3](#Fig3){ref-type="fig"}). Pooling the results revealed no significant difference between the two groups, with a WMD for the IOPR % comparing SLT with medication of −1.9 % (95 % CI: −5.00 %, 1.10 %) (Table [3](#Tab3){ref-type="table"}). When only including the RCTs, the differences in IOPR % were also statistically non-significant (Table [3](#Tab3){ref-type="table"}). Additionally, there was no significant heterogeneity in these analyses. Among the biases in the studies, the unit of analysis issue should be mentioned because there were 492 eyes of 366 patients, which lead to overestimate precision of effect estimates since within-patient correlation is not accounted for.Fig. 3Comparison of percent intraocular pressure reduction from the baseline between SLT group and topical medication group. WMDs indicate weighted mean difference, which were computed by using a random-effects model

Success rate {#Sec12}
------------

Five studies reported the proportions of patients achieving target endpoint IOP at follow-up endpoint; the difference in success rate between the SLT group and the medication group was not statistically significant (pooled OR 0.84, 95 % CI: 0.42, 1.68) (Fig. [4](#Fig4){ref-type="fig"}). No statistical heterogeneity was observed between studies (χ2 = 5.98, P = 0.200, I^2^ = 33.1 %).For the subgroup, including RCTs, the difference in success rate between the SLT group and the medication group was not statistically significant either (OR 0.85, 95 % CI: 0.34, 2.11). For the subgroup, including studies using latanoprost, the difference in success rate was not statistically significant (OR 0.57, 95 % CI: 0.23,1.38) (Table [3](#Tab3){ref-type="table"}).Fig. 4Comparison of success rates between SLT group and topical medication group. ORs indicate odds ratios, which were computed by using a random-effects model

Adverse events {#Sec13}
--------------

Concerning adverse events, three studies reported the types and incidences. However, we did not perform a meta-analysis because there were so few cases.In general, adverse events were transient and minor. Transient post-laser IOP spikein some patients was observed. There were no patients with sustained IOP elevation after SLT. Other common side effects, namely, anterior chamber reaction, discomfort, redness, and pain were also described as transient and without sequelae in all studies.

Sensitivity analysis and publication bias {#Sec14}
-----------------------------------------

The sensitivity analyses suggested that  each study did not significantly influence the global estimation of  the IOPR, IOPR %, and success rate (Table [4](#Tab4){ref-type="table"}). Due to the limited number (\<10) of studies included in each analysis, publication bias was not assessed. Table [5](#Tab5){ref-type="table"} summarized the overall evidence of SLT versus medicine in the treatment of OAG.Table 4Results of leave-one-out sensitivity analysesStudy ExcludedPooled WMD/ORTest for HeterogeneityTest for Overall EffectEstimateLowerUpχ2I^2^PZP**IOPR**Lai(2004)0.62−0.2371.481.220.00 %0.5421.420.156McIlraith(2006)0.86−0.1931.900.650.00 %0.7231.600.110Nagar(2009)0.43−0.481.330.370.00 %0.8290.930.353Katz(2012)0.51−0.611.641.250.00 %0.5360.890.371**IOPR%**Lai(2004)−2.50 %−6.60 %1.60 %3.7746.90 %0.1521.180.237McIlraith(2006)−3.20 %−9.10 %2.70 %3.7747.00 %0.1521.060.290Nagar(2009)−0.90 %−3.10 %1.30 %0.060.00 %0.9700.830.408Katz(2012)−3.90 %−9.60 %1.70 %2.6524.40 %0.2661.370.170**Success rate**Lai(2004)0.680.331.434.0225.4 %0.2591.010.311Nagar(2005)1.200.632.290.740.00 %0.8640.540.588McIlraith(2006)0.850.342.115.9849.8 %0.1130.350.726Nagar(2009)0.810.351.875.8348.6 %0.1200.500.620Katz(2012)0.780.331.855.5345.7 %0.1370.570.568CI = confidence interval; IOPR = intraocular pressure reduction; IOPR% = percent intraocular pressure reduction from baselineTable 5Summary of finding table of the overall quality of evidence according to GRADEOutcomesEye (Study)SLTMedAbsolute effect\
(95 % CI)Relative effect\
(95 % CI)Quality of evidenceRecommendIOPR325(4)1901350.60 (−0.24, 1.43)-BLowIOPR%325(4)190135−1.90 % (−5.00 %,1.10 %)-BLowSuccess rate298(4)1751230.84 (0.42,1.68)-CLow

Discussion {#Sec15}
==========

Introduced in 1995 by Park and Latina \[[@CR20]\], SLT provided a new choice for the reduction of IOP in eyes with OAG. SLT is easy to perform and well tolerated by patients.However, the efficacy and safety of SLT versus topical medications for OAG remain unclear. In the preliminary published studies, SLT was used as an adjunct therapy to medication \[[@CR21]\]. Later, several studies suggested that SLT may serve as the primary therapy for OAG \[[@CR22]--[@CR26]\]. Comparisons of SLT and medication were done in the remaining trials, but there is still not enough evidence to determine which is the best choice \[[@CR8]\].

In this meta-analysis, we reviewed five prospective comparative controlled trials. The results reveal that SLT is as effective as medication in regard to the control of IOP, which is consistent with a previous review \[[@CR8]\]. Also, no heterogeneity was observed across the studies.In addition, SLT and medication are similar in their success rates. The results from our subgroup and sensitivity analyses were quite similar and robust.

The exact mechanisms of SLT lowering IOP are not known. There are three prevailing theories, namely, the mechanical theory, the biologic theory, and the cell theory \[[@CR27], [@CR28]\] .According to the mechanical theory, contraction and shrinkage of trabecular beams caused by SLT exerts a pull on surrounding beams, which opens up the intertrabecular spaces.The biologic theory proposes that laser energy causes tissue injury with a resultant cascade of events. Macrophages are attracted and alter the secreted extracellular matrix, allowing an increased aqueous outflow.The cellular theory suggests that SLT applications stimulate cell division in the anterior trabecular meshwork, providing pluripotent cells for the repopulation of sites with laser therapy. These cells produce different extracellular matrices, enhancing the aqueous outflow. Additionally, there may be other mechanisms of action of SLT. It has been reported that exposure to factors secreted by lasered Schlemm canal cells and lasered trabecular meshwork cells and the application of prostaglandin analogs induced junction disassembly while increasing the permeability of Schlemm canal cells \[[@CR29]\]. Recently, Chen et al. \[[@CR30]\] determined the effect of travoprost (a drug similar to latanoprost) on Schlemm's canal in healthy human eyes using fourier-domain optical coherence tomography. They observed that travoprost induced the expansion of Schlemm's canal lumen. These findings suggest that SLT and latanoprost might share a common mechanism that likely mediated their similar IOP lowering effects.

The results of this meta-analysis must be interpreted cautiously in light of the strengths and limitations of the included trials. A key strength is the fact that all the studies included in this meta-analysis were published by established centers of excellence using a prospective comparative controlled design and all of them were well-performed and of high quality. Despite our rigorous methodology, some limitations of the current study should not be ignored. First, we cannot fully exclude publication bias. The number of included studies is insufficient to carry out statistical testing to detect publication bias. In addition, we did not attempt to gain access to unpublished results. Second, our analyses of IOPR, IOPR %, and success rate were based on data pooled from trials of different durations. This was due to the lack of data reported in all phases of follow-up and may have a potential impact on our results.Third, when discussing treatment result, it is important to realize that the criteria used to define success varies between studies. Differences between studies may also exist with respect to the diagnostic criteria for glaucoma and the severity of the disease. Fourth, none of the identified studies provided a cost-effectiveness analysis; thus, a prospective randomized clinical trial comparing the cost of SLT to medication is required. The effectsof SLT on other outcome measuressuch as delaying the need for surgery in people with early glaucoma were not assessed. This may be an interesting focus for future studies.

Conclusions {#Sec16}
===========

In conclusion, the present meta-analysis suggests that SLT appears to be similar to medication in lowering intraocular pressures in patients with open angle glaucoma. Despite our rigorous methodology, the inherent limitations of the included studies should be considered, and conclusions drawn from our pooled results should be interpreted with caution. Future large-volume, well-designed RCTs with extensive follow-up are awaited to confirm and update the findings of this analysis.
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